SARS-CoV-2 M pro inhibitors with antiviral activity in a transgenic mouse model.
Qiao, J., Li, Y.S., Zeng, R., Liu, F.L., Luo, R.H., Huang, C., Wang, Y.F., Zhang, J., Quan, B., Shen, C., Mao, X., Liu, X., Sun, W., Yang, W., Ni, X., Wang, K., Xu, L., Duan, Z.L., Zou, Q.C., Zhang, H.L., Qu, W., Long, Y.H., Li, M.H., Yang, R.C., Liu, X., You, J., Zhou, Y., Yao, R., Li, W.P., Liu, J.M., Chen, P., Liu, Y., Lin, G.F., Yang, X., Zou, J., Li, L., Hu, Y., Lu, G.W., Li, W.M., Wei, Y.Q., Zheng, Y.T., Lei, J., Yang, S.(2021) Science 371: 1374-1378
- PubMed: 33602867 
- DOI: https://doi.org/10.1126/science.abf1611
- Primary Citation of Related Structures:  
7C7P, 7COM, 7D3I - PubMed Abstract: 
The COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continually poses serious threats to global public health. The main protease (M pro ) of SARS-CoV-2 plays a central role in viral replication. We designed and synthesized 32 new bicycloproline-containing M pro inhibitors derived from either boceprevir or telaprevir, both of which are approved antivirals ...